Kidney Transplant Patient with a Facial Redness.
10.4285/jkstn.2015.29.4.238
- Author:
Jong Hwan JUNG
1
;
Jin Won JANG
;
Jin Han LIM
;
Ja Yeon LEE
;
Sik LEE
;
Hee Chul YU
;
Hong Pil HWANG
;
Sung Kwang PARK
Author Information
1. Department of Internal Medicine, Chonbuk National University Hospital, Chonbuk National University Medical School, Jeonju, Korea. parksk@jbnu.ac.kr
- Publication Type:Case Report
- Keywords:
Kidney transplantation;
Polycythemia;
Angiotensin receptor antagonists
- MeSH:
Adult;
Angiotensin Receptor Antagonists;
Angiotensins;
Cyclosporine;
Dizziness;
Headache;
Humans;
Incidence;
Kidney Transplantation;
Kidney*;
Lethargy;
Male;
Polycythemia
- From:The Journal of the Korean Society for Transplantation
2015;29(4):238-241
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Posttransplant erythrocytosis (PTE) is a common complication of renal transplantation, which can occur in approximately 10% to 15% of renal transplant patients and usually affects males with relatively good renal function. It is also associated with an increased incidence of thromboembolic events. Clinical manifestations of PTE include malaise, headache, plethora, lethargy, and dizziness. It is correlated with use of cyclosporin, gender, posttransplant renal function, and type of antihypertensive medication. The angiotensin receptor blocker (ARB) or angiotensin-converting enzyme inhibitor is preferred as an initial treatment for PTE because these agents are effective and reasonably safe in the majority of patients with PTE, and can also provide a necessary antihypertensive effect for kidney transplant patients. We report here on a 35-year-old male who had erythrocytosis after renal transplantation. After renal transplantation, his level of hemoglobin was 21 g/dL. We treated this patient with ARB and his symptoms and signs have been completely relieved.
